Epitope mapping of gp350/220 conserved domain of epstein barr virus to develop nasopharyngeal carcinoma (npc) vaccine

摘要

Nasopharyngeal carcinoma (NPC) is a malignant tumor in the nasopharyngeal epithelial cells that caused by many factors, one ofwhich is the viral infection of EBV (Epstein Barr Virus). The standard treatments to cure NPC still have not been encouraging. Theprevention through vaccination is an effective way to stop the disease. However, EBV vaccine being able to cover all variants ofvirus is still not available yet. Therefore, we identified the conserved region of glycoprotein 350/220 of EBV which hasimmunogenic and antigenic properties. The glycoprotein 350/220 is viral surface protein responsible to bind CR2 receptor,mediated EBV to enter the host cell. The conserved domain is crucial for EBV in infecting host cells. Further, by blocking CR2binding domain of gp350/220 using antibody will inhibit EBV's spreading, and provoke an immune system to eliminate the virusin a patient. Glycoprotein 350/220 from all variants of Epstein-Barr virus was retrieved from NCBI. The conserved domain ofgp350/220 was identified by aligning the protein sequences and structures. The polymorphic structure was used as a template fordocking analysis to identify the resemblance of amino acid from polymorphic variants of gp350/220 that binds CR2. The epitopemapping of gp350/220 was done by Discotope BepiPred method. The result revealed that the conserved region of gp350/220 waspredicted to have an epitope, QNPVYLIPETVPYIKWDNC residue, and it does not have any similarities to the human's cell surfaceprotein. Therefore, it can be used as a reference to develop vaccine to prevent NPC.